A 12-Week, Multicenter, Active-Treatment Extension Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type
ClinicalTrials.gov NCT03594123
Research payments
$717,644
Through program year 2023, $717,644 in research payments was reported against A 12-Week, Multicenter, Active-Treatment Extension Trial to Evaluate the Safety and Tolerability of Brexpiprazole in the Treatment of Subjects With Agitation Associated With Dementia of the Alzheimer's Type, across 68 payments, paid by Otsuka Pharmaceutical Development & Commercialization, Inc..
- Paid by
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- ClinicalTrials.gov
- NCT03594123
By program year
3 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2023 | Research | $139,710 | 26 |
| 2022 | Research | $335,872 | 22 |
| 2021 | Research | $242,062 | 20 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Shahin Shirzadi Houston, TX Named on 3 payments
- Hemant Pandey Chandler, AZ Named on 3 payments
- Gustavo Alva Costa Mesa, CA Named on 3 payments
- Leonardo Alonso Miami, FL Named on 3 payments
- Michael Pfeffer Miami, FL Named on 3 payments
- Gnyandev Patel Lakewood, CA Named on 3 payments
- Asad Islam Lewisville, TX Named on 2 payments
- Inna Yuryev-Golger Brooklyn, NY Named on 2 payments
- Perminder Bhatia Fresno, CA Named on 2 payments
- Jose Gamez Hialeah, FL Named on 2 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.